Should I buy or sell Harrow Health stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HROW shares. View HROW analyst ratings or view top-rated stocks .

What is Harrow Health's stock price target for 2024?

2 brokers have issued 1-year target prices for Harrow Health's stock. Their HROW share price targets range from $34.40 to $45.00. On average, they predict the company's share price to reach $38.80 in the next year. This suggests a possible upside of 330.2% from the stock's current price. View analysts price targets for HROW or view top-rated stocks among Wall Street analysts .

How have HROW shares performed in 2023?

Harrow Health's stock was trading at $14.76 at the beginning of the year. Since then, HROW shares have decreased by 38.9% and is now trading at $9.02. View the best growth stocks for 2023 here .

When is Harrow Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our HROW earnings forecast .

How were Harrow Health's earnings last quarter?

Harrow Health, Inc. (NASDAQ:HROW) posted its earnings results on Monday, November, 13th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.12. The company earned $34.27 million during the quarter, compared to analyst estimates of $37.58 million. Harrow Health had a negative net margin of 12.44% and a negative trailing twelve-month return on equity of 6.55%. The business's quarterly revenue was up 50.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.06) EPS.

What ETFs hold Harrow Health's stock?

ETFs with the largest weight of Harrow Health (NASDAQ:HROW) stock in their portfolio include Jacob Forward ETF (JFWD) and SPDR S&P Pharmaceuticals ETF (XPH) . Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) .

What guidance has Harrow Health issued on next quarter's earnings?

Harrow Health issued an update on its FY 2023 earnings guidance on Monday, November, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $129.00 million-$136.00 million, compared to the consensus revenue estimate of $141.53 million.

What other stocks do shareholders of Harrow Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA) , Aldeyra Therapeutics (ALDX) , OPKO Health (OPK) , QUALCOMM (QCOM) , SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , CymaBay Therapeutics (CBAY) , VBI Vaccines (VBIV) , Exelixis (EXEL) and Mustang Bio (MBIO) .

Who are Harrow Health's major shareholders?

Harrow Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Braidwell LP (5.15%), Morgan Stanley (5.06%), Private Capital Management LLC (4.04%), Invictus Private Wealth LLC (1.14%), Paradigm Capital Management Inc. NY (1.12%) and Stifel Financial Corp (0.97%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Martin A Makary, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom . View institutional ownership trends .

How do I buy shares of Harrow Health?

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Harrow Health Stock Price, News & Analysis (NASDAQ:HROW)

$9.06

-0.04 (-0.44%)

(As of 02:27 PM ET)

Compare

Today's Range: $8.72
▼
$9.06
50-Day Range: $8.10
▼
$16.36
52-Week Range: $7.60
▼
$28.25

Volume: 251,085 shs
Average Volume: 520,237 shs
Market Capitalization: $318.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $38.80

Harrow Health MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 330.6% Upside
$38.80 Price Target
Short Interest: Bearish
17.40% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.62
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$266,174 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.43) to $0.40 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

594th out of 935 stocks

Pharmaceutical Preparations Industry

279th out of 435 stocks

3.5

Analyst's Opinion

Consensus Rating
Harrow Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $38.80, Harrow Health has a forecasted upside of 330.6% from its current price of $9.01.
Amount of Analyst Coverage
Harrow Health has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
17.40% of the outstanding shares of Harrow Health have been sold short.
Short Interest Ratio / Days to Cover
Harrow Health has a short interest ratio ("days to cover") of 9.1.
Change versus previous month
Short interest in Harrow Health has recently decreased by 2.40%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Harrow Health does not currently pay a dividend.
Dividend Growth
Harrow Health does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HROW.

2.6

News and Social Media Coverage

News Sentiment
Harrow Health has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Harrow Health this week, compared to 2 articles on an average week.
Search Interest
6 people have searched for HROW on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.
MarketBeat Follows
5 people have added Harrow Health to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Harrow Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $266,174.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
13.60% of the stock of Harrow Health is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.75% of the stock of Harrow Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Harrow Health are expected to grow in the coming year, from ($0.43) to $0.40 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Harrow Health is -20.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Harrow Health is -20.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Harrow Health has a P/B Ratio of 8.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Harrow Health Stock (NASDAQ:HROW)

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

HROW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HROW Stock News Headlines

November 24, 2023 | seekingalpha.com

HROWM Harrow Health, Inc. NT CAL 27

November 20, 2023 | finance.yahoo.com

Harrow to Present at Two Investor Conferences in November

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 17, 2023 | benzinga.com

Harrow Recent Insider Activity

November 14, 2023 | msn.com

Harrow Health (NASDAQ:HROW) Plummets on Dismal Q3 Print

November 14, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Harrow Health (HROW), Synlogic (SYBX)

November 14, 2023 | markets.businessinsider.com

Why Is Eyecare-Focused Harrow Health Stock Trading Lower Today?

November 14, 2023 | finance.yahoo.com

Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript

November 28, 2023 | Edge On The Street (Ad)

Americans Now Favor Gold Over Stocks as an Investment Vehicle

Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.

November 13, 2023 | finance.yahoo.com

Harrow Announces Third Quarter 2023 Financial Results

November 5, 2023 | morningstar.com

Harrow Inc HROW

October 24, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), TELA Bio (TELA) and Harrow Health (HROW)

October 24, 2023 | finance.yahoo.com

Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.

October 18, 2023 | seekingalpha.com

Implications Of Harrow's Short-Term Guidance

September 29, 2023 | finance.yahoo.com

Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.

September 27, 2023 | seekingalpha.com

Harrow Health's 5-Year Guidance

September 26, 2023 | finance.yahoo.com

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation

September 21, 2023 | benzinga.com

Harrow Health 10% Owner Trades $292K In Company Stock

August 11, 2023 | finance.yahoo.com

Harrow Health, Inc. (NASDAQ:HROW) Q2 2023 Earnings Call Transcript

August 10, 2023 | seekingalpha.com

Harrow Health, Inc. 2023 Q2 - Results - Earnings Call Presentation

August 3, 2023 | fool.com

Harrow Health (NASDAQ: HROW)

August 1, 2023 | seekingalpha.com

Harrow Health And Its Interesting 11.6% 2027 Baby Bond

July 26, 2023 | bizjournals.com

Harrow Health inks deals for the rights to eight medications

July 19, 2023 | markets.businessinsider.com

Why Harrow Health Stock Is Trading Higher Today?

July 19, 2023 | finance.yahoo.com

Why Shares of Harrow Health Are Jumping Wednesday

July 19, 2023 | msn.com

Harrow prices $60 million stock offering, sees Q2 revenue in excess of $31M above consensus

July 19, 2023 | msn.com

Harrow acquires US and Canadian commercial rights for Santen’s Ophthalmic products

See More Headlines

Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:HROW
CUSIP: N/A
CIK: 1360214
Web: www.harrowinc.com
Phone: (615) 733-4730
Fax: 858-345-1745
Employees: 182
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $38.80
High Stock Price Target: $45.00
Low Stock Price Target: $34.40
Potential Upside/Downside: +326.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,090,000.00
Net Margins: -12.44%
Pretax Margin: -11.36%
Return on Equity: -6.55%
Return on Assets: -1.08%

Debt

Debt-to-Equity Ratio: 2.42
Current Ratio: 5.80
Quick Ratio: 5.33

Sales & Book Value

Annual Sales: $88.60 million
Price / Sales: 3.61
Cash Flow: $0.21 per share
Price / Cash Flow: 42.42
Book Value: $1.01 per share
Price / Book: 9.01

Miscellaneous

Outstanding Shares: 35,120,000
Free Float: 30,342,000
Market Cap: $319.59 million
Optionable: Optionable
Beta: 0.48

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Mark L. Baum J.D. (Age 49)
CEO & Chairman
Comp: $1.07M
Mr. Andrew R. Boll C.F.A. (Age 40)
C.M.A., CFA, CMA, CFO & Corp. Sec.
Comp: $716.73k
Dr. Robert J. Kammer D.D.S. (Age 73)
Special Advisor
Comp: $91.88k
Mr. John P. Saharek MBA (Age 62)
Chief Commercial Officer
Comp: $621.92k
Jamie Webb
Director of Communications & Investor Relations
Dr. Dennis E Saadeh Pharm.D.
Chief of Formulation Strategy
Mr. Andrew Livingston
Chief Innovation Officer
Ms. Kim Barratt
Chief Talent Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HROW Stock Analysis - Frequently Asked Questions

Should I buy or sell Harrow Health stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HROW shares.
View HROW analyst ratings or view top-rated stocks.
What is Harrow Health's stock price target for 2024?: 2 brokers have issued 1-year target prices for Harrow Health's stock. Their HROW share price targets range from $34.40 to $45.00. On average, they predict the company's share price to reach $38.80 in the next year. This suggests a possible upside of 330.2% from the stock's current price.
View analysts price targets for HROW or view top-rated stocks among Wall Street analysts.
How have HROW shares performed in 2023?: Harrow Health's stock was trading at $14.76 at the beginning of the year. Since then, HROW shares have decreased by 38.9% and is now trading at $9.02.
View the best growth stocks for 2023 here.
When is Harrow Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our HROW earnings forecast.
How were Harrow Health's earnings last quarter?: Harrow Health, Inc. (NASDAQ:HROW) posted its earnings results on Monday, November, 13th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.12. The company earned $34.27 million during the quarter, compared to analyst estimates of $37.58 million. Harrow Health had a negative net margin of 12.44% and a negative trailing twelve-month return on equity of 6.55%. The business's quarterly revenue was up 50.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.06) EPS.
What ETFs hold Harrow Health's stock?: ETFs with the largest weight of Harrow Health (NASDAQ:HROW) stock in their portfolio include Jacob Forward ETF (JFWD) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What guidance has Harrow Health issued on next quarter's earnings?: Harrow Health issued an update on its FY 2023 earnings guidance on Monday, November, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $129.00 million-$136.00 million, compared to the consensus revenue estimate of $141.53 million.
What other stocks do shareholders of Harrow Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).
Who are Harrow Health's major shareholders?: Harrow Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Braidwell LP (5.15%), Morgan Stanley (5.06%), Private Capital Management LLC (4.04%), Invictus Private Wealth LLC (1.14%), Paradigm Capital Management Inc. NY (1.12%) and Stifel Financial Corp (0.97%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Martin A Makary, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom.
View institutional ownership trends.
How do I buy shares of Harrow Health?: Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:HROW) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial